Bavarian Nordic Announces Results of a Phase 1 Trial Investigating Brachyury Specific Cancer Vaccine in Patients with Advanced Cancers
(Thomson Reuters ONE) -
* Novel Vaccine Induced Brachyury Specific T-cells in ~80% of Patients at
Higher Dose Levels
COPENHAGEN, Denmark, November 3, 2015 - Bavarian Nordic A/S (OMX: BAVA, OTC:
BVNRY) announced today results from an NCI-sponsored Phase 1 study investigating
its novel cancer vaccine, MVA-BN(®) Brachyury. Data from this study demonstrate
for the first time that an MVA-BN based vaccine targeting brachyury can induce
brachyury-specific T-cell immune responses in advanced cancer patients.
Led by the study's principal investigator Dr. Christopher R. Heery, M.D.,
Director of the Clinical Trials Group, Laboratory of Tumor Immunology and
Biology, Center for Cancer Research, National Cancer Institute, the Phase 1
dose-escalation study enrolled 13 patients with chordoma, a rare and slow
growing tumor which expresses brachyury, and 25 patients with other, metastatic
solid cancers. Brachyury is reported to play a key role in tumor metastasis.
Patients were enrolled in groups of three receiving escalating doses of MVA-BN
Brachyury in three cycles, every four weeks. Once safety was established,
additional patients were enrolled at the two highest doses.
MVA-BN Brachyury was well tolerated with no dose limiting toxicities. The
maximal tolerated dose was not reached. No serious adverse vaccine-related
events were observed. Immune responses were analyzed in 29 patients. Brachyury-
specific T-cell responses were observed at each dose level: 66% of patients at
dose level 1, 80% at dose level 2, and 90% at dose level 3. At the two highest
dose levels, approximately 80% of the patients that developed brachyury-specific
T-cells demonstrated responses in both CD4 and CD8 T-lymphocytes.
"This is very positive news on many levels," said Paul Chaplin, President and
Chief Executive Officer of Bavarian Nordic. "For one, we now have confirmation
that an MVA-BN based cancer immunotherapy can elicit a T-cell response against a
specific tumor target. Additionally, finding a therapeutic approach to treating
brachyury expression, which is not normally found on a tumor cell surface, has
to date proven to be quite difficult. The creation of a vaccine-based,
immunotherapy approach could be a unique solution to targeting a tumor antigen
which has been associated with high rates of metastasis and multi-drug
resistance. We thank our partners at the NCI for conducting this study, and look
forward to working with them to advance this program in the coming years,"
The results will be presented as a poster at the Society for Immunotherapy of
Cancer's Annual Meeting in National Harbor, Maryland, on Saturday, November
7(th), from 12:45-2:00 pm ET. An abstract entitled "Phase 1, dose escalation,
clinical trial of MVA-Brachyury-TRICOM Vaccine demonstrating safety and
brachyury-specific T cell responses" is available online at
www.immunotherapyofcancer.org/supplements.
Contacts
Rolf Sass Sørensen
Vice President Investor Relations (EU)
Tel: +45 61 77 47 43
Seth Lewis
Vice President Investor Relations (US)
Tel: +1 978 341 5271
About MVA-BN Brachyury
MVA-BN Brachyury is a novel, active immunotherapy candidate designed to induce a
robust T-cell immune response against brachyury, a tumor-associated antigen
which is overexpressed in every major solid tumor setting. Brachyury is believed
to play a key role in both the metastasis and progression of tumors. Tumors
which overexpress brachyury are believed to be highly resistant to current
therapies and are associated with decreased survival rates.
MVA-BN Brachyury is being developed using Bavarian Nordic's proprietary
validated MVA-BN (Modified Vaccinia Ankara Bavarian Nordic) platform. In
clinical studies comprising more than 7,600 subjects, including cancer patients,
MVA-BN has been shown to be well-tolerated and to induce a strong immune
response.
About Bavarian Nordic
Bavarian Nordic is a fully integrated biotechnology company focused on the
development, manufacturing and commercialization of cancer immunotherapies and
vaccines for infectious diseases, based on the Company's live virus vaccine
platform. Through long-standing collaborations, including a collaboration with
the U.S. government, Bavarian Nordic has developed a portfolio of vaccines for
infectious diseases, including the non-replicating smallpox vaccine,
IMVAMUNE(®), which is stockpiled for emergency use by the United States and
other governments. The vaccine is approved in the European Union (under the
trade name IMVANEX(®)) and in Canada. Bavarian Nordic and its partner Janssen
are developing an Ebola vaccine regimen, which has been fast-tracked, with the
backing of worldwide health authorities. Additionally, in collaboration with the
National Cancer Institute, Bavarian Nordic has developed a portfolio of active
cancer immunotherapies, including PROSTVAC(®), which is currently in Phase 3
clinical development for the treatment of advanced prostate cancer. The company
has partnered with Bristol-Myers Squibb for the potential commercialization of
PROSTVAC. For more information visit www.bavarian-nordic.com or follow us on
Twitter (at)bavariannordic.
Forward-looking statements
This announcement includes forward-looking statements that involve risks,
uncertainties and other factors, many of which are outside of our control, that
could cause actual results to differ materially from the results discussed in
the forward-looking statements. Forward-looking statements include statements
concerning our plans, objectives, goals, future events, performance and/or other
information that is not historical information. All such forward-looking
statements are expressly qualified by these cautionary statements and any other
cautionary statements which may accompany the forward-looking statements. We
undertake no obligation to publicly update or revise forward-looking statements
to reflect subsequent events or circumstances after the date made, except as
required by law.
201531en:
http://hugin.info/100065/R/1963670/716583.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Bavarian Nordic A/S via GlobeNewswire
[HUG#1963670]
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="Sirona Biochem Retains Strategic Advisor to Commercialize Glycoproteins
Datum: 03.11.2015 - 14:00 Uhr
Sprache: Deutsch
News-ID 431545
Anzahl Zeichen: 7161
contact information:
Town:
Kvistgård
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 232 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Bavarian Nordic Announces Results of a Phase 1 Trial Investigating Brachyury Specific Cancer Vaccine in Patients with Advanced Cancers"
steht unter der journalistisch-redaktionellen Verantwortung von
Bavarian Nordic A/S (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
